uninsured women with breast cancer, we compared insured and uninsured women treated in a safety net setting. Controlling for … that, despite the safety net system, uninsured women with breast cancer are likely to require more costly treatment and to … have worse outcomes, relative to insured women with breast cancer …

recommendation. We explore this distinction in the context of recommendations that breast cancer screening start at age 40. The raw … data suggest that responders to the age 40 recommendation have less cancer than do women who self-select into screening at … recommendation also have less cancer than women who never screen, suggesting that the benefits of recommending early screening are …

. These treatments promise to dramatically raise durable survival rates for a growing number of cancer patients but are often … immunotherapy for melanoma patients. Extrapolating to 17 other cancer sites, we estimate the insurance sector's benefit to equal $6 …

(before ages 75, 65, and 55) cancer mortality and hospitalization, by estimating difference-in-differences models based on … longitudinal, cancer-site-level data on about 30 cancer sites. The estimates indicate that cancer sites about which more research …-2013, controlling for the change in the number of people diagnosed. Cancer sites for which more non-research-supported articles were …

paper analyzes the influence of physician investigators who lead clinical trials for new cancer drugs. By comparing … diffusion patterns across 21 new cancer drugs, we separate correlated regional demand for new technology from information …

For decades, the US public and private sectors have committed substantial resources towards cancer research, but the … societal payoff has not been well-understood. We quantify the value of recent gains in cancer survival, and analyze the … distribution of value among various stakeholders. Between 1988 and 2000, life expectancy for cancer patients increased by roughly …

substantially all” oral anti-cancer medications on plans' formularies. We exploited exogenous variation in the age of diagnosis for … different cancer sites - and therefore the relative expansion in market size for different cancers under the Medicare …